UK company Prokarium has raised $10 million to develop groundbreaking synthetic biology techniques to create a new generation of vaccines, which could be taken orally, and not have to be ke
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
